KIRSTEN FLOWERS - 26 Jan 2022 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Commercial Officer
Signature
Teresa Bair, Attorney-in-fact for Kirsten Flowers
Issuer symbol
KURA
Transactions as of
26 Jan 2022
Net transactions value
$0
Form type
4
Filing time
28 Jan 2022, 15:13:20 UTC
Previous filing
10 Jan 2022
Next filing
20 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +21,900 +3584% $0.000000 22,511 26 Jan 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +171,000 $0.000000 171,000 26 Jan 2022 Common Stock 171,000 $14.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26.
F2 Includes 611 shares acquired on November 20, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
F3 This option vests in 48 equal monthly installments commencing on the grant date.